Accéder au contenu
Merck
Toutes les photos(1)

Documents

481480

Sigma-Aldrich

NF-κB SN50

≥97% (HPLC), lyophilized, NF-κB translocation inhibitor, Calbiochem®

Synonyme(s) :

NF-κB SN50, Cell-Permeable Inhibitor Peptide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C129H230N36O29S
Poids moléculaire :
2781.50
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

product name

NF-κB SN50, Cell-Permeable Inhibitor Peptide, NF-κB SN50, CAS 213546-43-3, is a cell-permeable peptide that contains the NLS sequence of NF-κB p50 linked to the hydrophobic region of K-FGF. Inhibits translocation of the NF-κB into the nucleus.

Niveau de qualité

Pureté

≥97% (HPLC)

Forme

lyophilized

Fabricant/nom de marque

Calbiochem®

Conditions de stockage

OK to freeze
desiccated (hygroscopic)

Solubilité

water: 5 mg/mL

Conditions d'expédition

ambient

Température de stockage

−20°C

Description générale

Contains the nuclear localization sequence (NLS) of the transcription factor NF-κB p50 linked to the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). The N-terminal K-FGF h-region confers cell-permeability, while the NLS (360-369) inhibits translocation of the NF-κB active complex into the nucleus. In murine endothelial LE-II cells induced by LPS, NF-κB nuclear translocation is maximally inhibited at 18 µM.
Contains the nuclear localization sequence (NLS) of the transcription factor NF-κB p50 linked to the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). The peptide N-terminal K-FGF h-region confers cell-permeability, while the NLS (360-369) inhibits translocation of the NF-κB active complex into the nucleus. In murine endothelial LE-II cells induced by LPS, inhibition of NF-κB nuclear translocation is maximally inhibited at 18 µM.
NF-κB SN50, CAS 213546-43-3, is a cell-permeable peptide that contains the NLS sequence of NF-κB p50 linked to the hydrophobic region of K-FGF. Inhibits translocation of the NF-κB into the nucleus.

Actions biochimiques/physiologiques

Cell permeable: yes
Primary Target
translocation of the NF-κB active complex into the nucleus
Product does not compete with ATP.

Avertissement

Toxicity: Standard Handling (A)

Séquence

H-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH

Forme physique

Supplied as a trifluoroacetate salt.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Avoid freeze/thaw cycles of solutions.

Autres remarques

Lin, Y.-Z., et al. 1995. J. Biol. Chem. 270, 14255.

Informations légales

Sold under license of U.S. Patents 5,807,746 and 6,043,339 for research use only. Licenses for commercial manufacture, commercial use, diagnostics, or therapeutics may be obtained by contacting Vanderbilt University, Nashville, Tennessee.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Johanna R Reed et al.
PloS one, 7(9), e45877-e45877 (2012-10-03)
Tumor formation is an extensive process requiring complex interactions that involve both tumor cell-intrinsic pathways and soluble mediators within the microenvironment. Tumor cells exploit the intrinsic functions of many soluble molecules, including chemokines and their receptors, to regulate pro-tumorigenic phenotypes
Taewoo Yang et al.
Journal of experimental & clinical cancer research : CR, 41(1), 82-82 (2022-03-05)
BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistance remain unclear. In silico bioinformatic analysis was performed to identify the most active transcription factor

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique